# Ipamorelin Research: Mechanism, Studies, and the Stack Comparisons > Ipamorelin research: the GHS-R1a selectivity mechanism, the founding 1998 study, human PK, the failed Phase 2 trial, and how it compares to CJC-1295, sermorelin, and tesamorelin. Cited. Selectivity, half-life, the one human trial, and the GHRH-analog stacks — read against the studies that ran them. ## Before the details Here is the ipamorelin research in plain terms. The body makes its own growth hormone (GH) in pulses, mostly at night. Ipamorelin is a lab-made peptide that pushes one of those pulses by hitting the same cell receptor that the natural hunger hormone, ghrelin, uses. What made it notable in 1998 was precision: it raised GH without dragging up cortisol or prolactin, the way older peptides did. The numbers that hold up are small and specific — a roughly two-hour half-life in people, a single GH pulse about 40 minutes after a dose, and dose-dependent bone growth in rats. The one human efficacy trial failed. Most of what you read online about "ipamorelin CJC-1295" stacks comes from the pharmacology of each peptide separately, not from a trial of the two together. Below, each finding is pinned to its study. ## Mechanism: selective GH release Ipamorelin activates GHS-R1a — the growth-hormone-secretagogue receptor type 1a, which is the ghrelin receptor — on pituitary somatotrophs (the GH-making cells). Receptor activation runs through the Gq/PLC pathway, raises intracellular calcium, and releases GH. The defining result: in primary rat pituitary cells, anaesthetised rats, and conscious swine, ipamorelin released GH as potently as GHRP-6 (swine ED50 = 2.3 nmol/kg vs 3.9 nmol/kg), yet did not raise ACTH or cortisol above the GHRH baseline even above 200-fold its GH ED50 [1]. That dissociation — strong GH, flat stress hormones — is the selectivity that names the compound. The mechanism is distinct from, and complementary to, GHRH (growth-hormone-releasing hormone), which works through a separate cAMP pathway. That complementarity is the pharmacological basis for combining ipamorelin with a GHRH analog. In ovine pituitary cells, GHRH + GHRP-2 together raised GH mRNA, GHS-R, GHRH-R, and Pit-1 expression, and GHRP-2 suppressed both somatostatin-receptor subtypes while GHRH raised only one [8] — a molecular account of why a GHRP and a GHRH analog amplify each other. A broader review confirms this synergy is a class-wide property: GHRPs stay partly active under conditions (glucose, free fatty acids, somatostatin) that nearly abolish GHRH alone [9]. The neuroendocrine circuit basis — ghrelin co-localizing with GHRH and inhibiting somatostatin — is laid out in a 2021 review [11]. ## What is ipamorelin peptide Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (molecular formula C38H49N9O5, ~711.9 Da, CAS 170851-70-4). It is not a natural human peptide; it mimics ghrelin's action at GHS-R1a. The design is deliberate: the alpha-aminoisobutyric acid at position 1 and the D-amino acids confer resistance to enzymatic breakdown, and the molecule was derived from GHRP-1 by removing a central dipeptide [1]. It was the first growth-hormone secretagogue characterized as highly GH-selective, which is the property that distinguishes "ipamorelin peptide" from the broader GHRP family. ## Human pharmacokinetics Population PK/PD modeling in healthy male volunteers (n=8 per dose; five 15-minute IV infusions of 4.21-140.45 nmol/kg) showed dose-proportional, linear kinetics: terminal half-life approximately 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg, and a single GH pulse peaking near 0.67 h (40 minutes) after dosing [2]. This is one of the only human ipamorelin datasets in existence and the source of the half-life figure that propagates everywhere. It is detailed on the [half-life page](/half-life). ## The one human efficacy trial The only published Phase 2 RCT (NCT00672074) enrolled 114 adults undergoing bowel resection, dosed 0.03 mg/kg IV twice daily for up to 7 days, and measured time to first tolerated meal. It missed: 25.3 h with ipamorelin vs 32.6 h placebo, p=0.15 [3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm vs 94.8% of placebo — no ipamorelin-specific safety signal in that short perioperative window, but also no demonstrated efficacy. This is the defining human anchor for ipamorelin, and it is a negative one. ## Preclinical efficacy and the recent record In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 μg/day (divided three times daily for 15 days) raised longitudinal bone-growth rate dose-dependently from 42 μm/day (vehicle) to 44, 50, and 52 μm/day — with no change in total IGF-1, IGFBPs, or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect [4]. In streptozotocin-diabetic mice, IV ipamorelin produced greater GH hypersecretion (150 ± 35 µg/L) than non-diabetic controls (62 ± 11 µg/L), alongside hepatic GH-receptor resistance and suppressed IGF-I — altered pharmacodynamics in a diabetic state [7]. The most recent in-vivo study (2024 ferret cachexia model) found intraperitoneal ipamorelin (1-3 mg/kg) inhibited cisplatin-induced weight loss by ~24% in the delayed phase, but had no anti-emetic effect on either acute or delayed emesis [5]. Recent narrative reviews (2026) place ipamorelin as an investigational GH-axis secretagogue with preclinical musculoskeletal signals and explicitly flag the absence of rigorous human trials and the potential for serious harm [16][18]. ## Ipamorelin cjc-1295 Ipamorelin cjc-1295 is the most-searched pairing in this space. CJC-1295 is a GHRH analog; ipamorelin is a GHRP. They act on two different receptors through two different pathways, and the rationale for combining them is the complementary mechanism documented above [8][9][11]. A 2026 orthopaedic narrative review reports that CJC-1295 + ipamorelin improved maximum tetanic muscle tension in a murine glucocorticoid-induced muscle-loss model — while stating that the evidence is limited to animal studies [15]. There is no trial of the combination for any human outcome. Every claim about the stack is an extrapolation from each agent's separate single-agent pharmacology, not a tested combined result. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin is a comparison across two drug classes, not two versions of the same thing. Sermorelin is a GHRH analog (GHRH 1-29) that acts on the GHRH receptor; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist [1]. They raise GH by separate, complementary mechanisms — which is exactly why GHRH analogs and GHRPs are studied together rather than as substitutes [9][11]. Ipamorelin's distinguishing feature within its own class is selectivity: GH release without the cortisol and prolactin bump seen with other GHRPs [1]. A head-to-head human efficacy comparison of the two compounds is not part of the published record. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is, again, GHRP versus GHRH analog. Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor; ipamorelin acts on the ghrelin receptor [1]. The mechanistic relationship is complementary, not competitive — the two receptor systems converge on GH but enter through different doors [8][11]. The published ipamorelin literature does not include a direct comparative trial against tesamorelin; what exists is the separate single-agent pharmacology of each, summarized in the class reviews [9][11]. --- A safety-led readout of the ipamorelin record — the reported side effects, the water-retention question, and the lone failed human trial logged first, with the long-term-safety line left openly blank; no clinic behind the console and nothing here dosed, prescribed, or sold.